Introduction:The genomic-based 21-gene recurrence score assay (21-GRSA) allows to determine the usefulness of adjuvant chemotherapy in patients with luminal-type early breast cancer (LTEBC).Additional predictive models have also been developed, such as Magee equations (ME), the Predict model (PM), and the Tennessee nomogram score (TNS).Objective: To evaluate the concordance between 21-GRSA, ME, PM and TNS.Methods: Patients with unifocal LTEBC and 21-GRSA, ME, PM and TNS results were included.A subgroup analysis of women older than 50 years was carried out.Concordance between the models and 21-GRSA was evaluated using Cohen's kappa index (KI).Results: One-hundred and twenty-two women were included.Concordance between 21-GRSA and ME (KI = 0.35) and PM (KI = 0.24) was fair (p < 0.001).Concordance between 21-GRSA and TNS was inferior (KI = 0.16, p = 0.04).Eighty patients older than 50 years with sufficient data to calculate all three predictive models were included.Concordance was found between the low-risk classification on 21-GRSA and all three combined models in 36/37 patients (negative predictive value of 97.3%).Conclusion: 21-GRSA can be omitted in women older than 50 years with LTEBC classified with low risk scores on all three predictive models.